Catinazzo Thomas 4

What Happened
Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (RLAY), sold 17,717 shares on May 14, 2026. The weighted average sale price was $12.86 per share for total proceeds of approximately $227,841. The transaction is reported as a sale (S) and was effected under a Rule 10b5‑1 trading plan.

Key Details

• Transaction date: 2026-05-14 (reported same day).
• Transaction type/code: Open market sale (S); effected pursuant to a 10b5‑1 plan adopted October 30, 2025 (Footnote F1).
• Price details: Executed in multiple trades at prices ranging $12.67 to $13.42; $12.86 is the weighted average (Footnote F2). Reporting person can provide breakdown by price on request.
• Proceeds: ~ $227,841 (17,717 shares × $12.86 weighted average).
• Shares owned after transaction: Not explicitly stated in the summary provided; filing footnote indicates holdings include 9,807 shares underlying restricted stock units (RSUs) (Footnote F3).
• Timeliness: Filing covers the transaction date 2026-05-14 and was filed the same day (no late filing indicated).

Context
A sale under a pre-established Rule 10b5‑1 plan typically reflects scheduled, pre-authorized trading activity rather than an ad hoc decision by the insider; it reduces but does not eliminate inferences about the insider’s view. Footnote F2 indicates the sale was executed across multiple prices and the filer will disclose per‑trade quantities/prices on request. The inclusion of 9,807 RSUs in footnote F3 relates to reported beneficial ownership and does not itself indicate a separate sale or transfer.